Overview

A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer

Status:
Active, not recruiting

Trial end date:
2021-10-31

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to look at the potential effects of paricalcitol (a drug similar to vitamin D) on pancreatic tumors in patients who are planned for surgical removal of their tumor. The study will also look at the safety of paricalcitol prior to surgery.

Phase:

Phase 1

Details

Lead Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Treatments:

Ergocalciferols